ImmunoPrecise Antibodies Ltd.
IPA
$0.4379
$0.01092.55%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -663.46% | -5.32% | -14.05% | -251.17% | 43.10% |
| Total Depreciation and Amortization | 0.01% | 2.69% | -10.13% | 208.85% | -22.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -97.65% | -- |
| Total Other Non-Cash Items | 3,176.24% | -298.93% | -143.28% | 387.99% | -59,571.43% |
| Change in Net Operating Assets | -23.59% | -202.13% | 66.73% | 91.10% | 267.78% |
| Cash from Operations | -10.74% | -12,251.13% | -221.38% | -18.09% | 70.94% |
| Capital Expenditure | -164.48% | 78.38% | -88.52% | -143.48% | 167.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -667.38% |
| Cash from Investing | -286.73% | 79.29% | -30.06% | -149.79% | 125.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.90% | -31.29% | 2.72% | 20.94% | 15.04% |
| Issuance of Common Stock | 1,044.81% | -- | -- | 142,400.00% | 863.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,534.60% | 763.73% | 748.52% | 394.21% | 317.02% |
| Foreign Exchange rate Adjustments | -73.42% | -101.77% | 62.29% | -805.93% | 72.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,720.00% | 46.83% | 128.55% | 9.99% | 104.94% |